Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2018

Conditions
Hematological MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

NiCord®

Trial Locations (15)

10043

University of Turin, Turin

11040

Steven and Alexandra Cohen Children's Medical Center, New York

16147

Children Hospital Gaslini Scientific Institute, Genoa

27710

Duke University Medical Center, Durham

37240

Vanderbilt, Nashville

44195

Cleveland Clinic, Cleveland

46009

Hospital Universitario La Fe, Valencia

55455

University of Minnesota, Minneapolis

60153

Loyola University, Cardinal Bernardin Cancer Center, Maywood

90048

Cedars-Sinai Medical Center, Los Angeles

97239

Oregon Health & Science University, Portland

119074

National University Cancer Institute, Singapore

169608

Singapore General Hospital, Singapore

3503 AB

University Medical Center Utrecht, Utrecht

08035

University Hospital Vall d´Hebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gamida Cell ltd

INDUSTRY